126 related articles for article (PubMed ID: 38008278)
21. ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression.
Fan Y; Hou T; Dan W; Zhu Y; Liu B; Wei Y; Wang Z; Gao Y; Zeng J; Li L
Cell Death Differ; 2022 Aug; 29(8):1611-1624. PubMed ID: 35194188
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.
Theurillat JP; Udeshi ND; Errington WJ; Svinkina T; Baca SC; Pop M; Wild PJ; Blattner M; Groner AC; Rubin MA; Moch H; Prive GG; Carr SA; Garraway LA
Science; 2014 Oct; 346(6205):85-89. PubMed ID: 25278611
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
Wu F; Dai X; Gan W; Wan L; Li M; Mitsiades N; Wei W; Ding Q; Zhang J
Cancer Lett; 2017 Jan; 385():207-214. PubMed ID: 27780719
[TBL] [Abstract][Full Text] [Related]
24. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.
Shoag J; Liu D; Blattner M; Sboner A; Park K; Deonarine L; Robinson BD; Mosquera JM; Chen Y; Rubin MA; Barbieri CE
J Clin Invest; 2018 Jan; 128(1):381-386. PubMed ID: 29202479
[TBL] [Abstract][Full Text] [Related]
25. SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions.
Jiang Q; Zheng N; Bu L; Zhang X; Zhang X; Wu Y; Su Y; Wang L; Zhang X; Ren S; Dai X; Wu D; Xie W; Wei W; Zhu Y; Guo J
Mol Cancer; 2021 Aug; 20(1):100. PubMed ID: 34353330
[TBL] [Abstract][Full Text] [Related]
26. Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
Shi Q; Zhu Y; Ma J; Chang K; Ding D; Bai Y; Gao K; Zhang P; Mo R; Feng K; Zhao X; Zhang L; Sun H; Jiao D; Chen Y; Sun Y; Zhao SM; Huang H; Li Y; Ren S; Wang C
Mol Cancer; 2019 Nov; 18(1):170. PubMed ID: 31771591
[TBL] [Abstract][Full Text] [Related]
27. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
[TBL] [Abstract][Full Text] [Related]
28. SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression.
Ma J; Chang K; Peng J; Shi Q; Gan H; Gao K; Feng K; Xu F; Zhang H; Dai B; Zhu Y; Shi G; Shen Y; Zhu Y; Qin X; Li Y; Zhang P; Ye D; Wang C
J Exp Clin Cancer Res; 2018 Jul; 37(1):145. PubMed ID: 29996942
[TBL] [Abstract][Full Text] [Related]
29. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
[TBL] [Abstract][Full Text] [Related]
30. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.
An J; Wang C; Deng Y; Yu L; Huang H
Cell Rep; 2014 Feb; 6(4):657-69. PubMed ID: 24508459
[TBL] [Abstract][Full Text] [Related]
31. Deficiency in SPOP-mediated ubiquitination and degradation of TIAM1 promotes gastric cancer progression.
Liu F; Zhang T; Sun X; Liu Z; Xu W; Dai X; Zhang X
Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167032. PubMed ID: 38246227
[TBL] [Abstract][Full Text] [Related]
32. The CUL3-SPOP-DAXX axis is a novel regulator of VEGFR2 expression in vascular endothelial cells.
Sakaue T; Sakakibara I; Uesugi T; Fujisaki A; Nakashiro KI; Hamakawa H; Kubota E; Joh T; Imai Y; Izutani H; Higashiyama S
Sci Rep; 2017 Feb; 7():42845. PubMed ID: 28216678
[TBL] [Abstract][Full Text] [Related]
33. SPOP suppresses prostate cancer through regulation of CYCLIN E1 stability.
Ju LG; Zhu Y; Long QY; Li XJ; Lin X; Tang SB; Yin L; Xiao Y; Wang XH; Li L; Zhang L; Wu M
Cell Death Differ; 2019 Jun; 26(6):1156-1168. PubMed ID: 30237511
[TBL] [Abstract][Full Text] [Related]
34. SPOP promotes cervical cancer progression by inducing the movement of PD-1 away from PD-L1 in spatial localization.
Wu J; Wu Y; Guo Q; Chen S; Wang S; Wu X; Zhu J; Ju X
J Transl Med; 2022 Aug; 20(1):384. PubMed ID: 36042498
[TBL] [Abstract][Full Text] [Related]
35. Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.
Nikhil K; Haymour HS; Kamra M; Shah K
Br J Cancer; 2021 Mar; 124(5):995-1008. PubMed ID: 33311589
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Dai X; Gan W; Li X; Wang S; Zhang W; Huang L; Liu S; Zhong Q; Guo J; Zhang J; Chen T; Shimizu K; Beca F; Blattner M; Vasudevan D; Buckley DL; Qi J; Buser L; Liu P; Inuzuka H; Beck AH; Wang L; Wild PJ; Garraway LA; Rubin MA; Barbieri CE; Wong KK; Muthuswamy SK; Huang J; Chen Y; Bradner JE; Wei W
Nat Med; 2017 Sep; 23(9):1063-1071. PubMed ID: 28805820
[TBL] [Abstract][Full Text] [Related]
37. Reduction of oligomer size modulates the competition between cluster formation and phase separation of the tumor suppressor SPOP.
Sabri N; Cuneo MJ; Marzahn MR; Lee J; Bouchard JJ; Güllülü Ö; Vaithiyalingam S; Borgia MB; Schmit J; Mittag T
J Biol Chem; 2023 Dec; 299(12):105427. PubMed ID: 37926283
[TBL] [Abstract][Full Text] [Related]
38. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer.
Li G; Ci W; Karmakar S; Chen K; Dhar R; Fan Z; Guo Z; Zhang J; Ke Y; Wang L; Zhuang M; Hu S; Li X; Zhou L; Li X; Calabrese MF; Watson ER; Prasad SM; Rinker-Schaeffer C; Eggener SE; Stricker T; Tian Y; Schulman BA; Liu J; White KP
Cancer Cell; 2014 Apr; 25(4):455-68. PubMed ID: 24656772
[TBL] [Abstract][Full Text] [Related]
39. Daxx-mediated transcriptional repression of MMP1 gene is reversed by SPOP.
La M; Kim K; Park J; Won J; Lee JH; Fu YM; Meadows GG; Joe CO
Biochem Biophys Res Commun; 2004 Jul; 320(3):760-5. PubMed ID: 15240113
[TBL] [Abstract][Full Text] [Related]
40. ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance.
Lee CJ; Lee H; Kim SR; Nam SB; Lee GE; Yang KE; Lee GJ; Chun SH; Kang HC; Lee JY; Lee HS; Cho SJ; Cho YY
Cell Death Dis; 2024 Apr; 15(4):274. PubMed ID: 38632244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
